India, Oct. 22 -- Alpha Tau Medical (DRTS, DRTSW) announced that it has signed a memorandum of understanding (MOU) with Samsung Medical Center in Seoul, South Korea, to explore a potential clinical trial of its Alpha DaRT cancer therapy in patients with pancreatic cancer.
The proposed study would mark Alpha DaRT's first potential clinical trial in South Korea. Any trial would be subject to regulatory and ethics committee approvals.
Pancreatic cancer remains a major treatment challenge in South Korea. According to the company, 9,748 people were diagnosed with the disease in 2023, and the five-year relative survival rate was 17%. Many patients are diagnosed at an advanced stage, limiting treatment options.
Samsung Medical Center's Pancreat...